[
    [
        {
            "time": "2023-10-17",
            "original_text": "FDA Approves Eli Lilly's Jardiance For Heart Failure",
            "features": {
                "keywords": [
                    "FDA",
                    "Approves",
                    "Eli Lilly",
                    "Jardiance",
                    "Heart Failure"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "FDA Approves Eli Lilly's Jardiance For Heart Failure",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "Is Eli Lilly (LLY) A Smart Long-Term Buy?",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Long-Term Buy"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Is Eli Lilly (LLY) A Smart Long-Term Buy?",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction",
            "features": {
                "keywords": [
                    "US FDA",
                    "approves",
                    "Jardiance",
                    "heart failure",
                    "reduced ejection fraction"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "3 Big Drug/Biotech Outperformers Worth Keeping an Eye On",
            "features": {
                "keywords": [
                    "Drug",
                    "Biotech",
                    "Outperformers"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 Big Drug/Biotech Outperformers Worth Keeping an Eye On",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline",
            "features": {
                "keywords": [
                    "Daily Biotech Pulse",
                    "AzurRx",
                    "Agios",
                    "Mitapivat",
                    "Priority Review",
                    "FDA Nod",
                    "GlaxoSmithKline"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]